Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-latrotoxin (α-LTX) is a potent 130 kDa neurotoxin derived from the venom of spiders in the genus Latrodectus, most notably the black widow spider (Latrodectus mactans). It acts specifically at the presynaptic nerve terminals of vertebrates, where it induces a massive and exhaustive release of neurotransmitters such as acetylcholine, GABA, and glutamate (Südhof, 2001, PMID: 11773605). The toxin exerts its effects through two distinct pathways: by forming non-selective cation pores in the presynaptic membrane and by binding to high-affinity receptors, including latrophilin-1 (a G protein-coupled receptor) and neurexin-1α (Ushkaryov et al., 2008, PMID: 18411248). This dual mechanism leads to an influx of calcium and the stimulation of the exocytotic machinery, resulting in the clinical syndrome known as latrodectism. Latrodectism is characterized by severe muscle pain, abdominal rigidity, and autonomic instability, which can be life-threatening in vulnerable populations (StatPearls, 2023). While α-LTX is a significant public health concern, it is also a valuable pharmacological tool used to study the molecular basis of synaptic vesicle docking and fusion. Therapeutic management typically involves supportive care and the administration of equine-derived antivenom to neutralize the circulating toxin (Isbister & Fan, 2011, PMID: 21663530).
Alpha-latrotoxin binds to presynaptic receptors (latrophilin and neurexin) and inserts into the membrane to form cation-selective pores, leading to massive, uncontrolled neurotransmitter release (PMID: 11773605, 18411248).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha-latrotoxin (α-LTX) (α-LTX).